Alivus Life Sciences reported a strong Q3 FY26, highlighted by a significant recovery in its CDMO business. Overall revenue reached ₹6,729 Mn, a 14.4% increase QoQ. EBITDA margins improved to 36.4%, up 510 bps YoY, driven by new launches and operational efficiencies. Non-GPL revenues continue to grow robustly, increasing by 16.1% YoY for 9MFY26.
Financial Performance
Alivus Life Sciences announced its Q3 FY26 results, demonstrating a solid operational improvement:
- Revenue: Reported at ₹6,729 Mn, reflecting a 14.4% growth QoQ and 4.8% growth YoY. For 9MFY26, revenues reached ₹18,627 Mn, a 7.2% YoY increase.
- EBITDA: Stood at ₹2,452 Mn with margins at 36.4%, a significant increase of 510 bps YoY.
- PAT: Reached ₹1,503 Mn, with a 15.5% QoQ growth.
Segmental Performance
The company experienced notable performance across its key segments:
- CDMO: Demonstrated substantial recovery, with revenues growing 100% QoQ and 85.3% YoY. This growth was supported by traction in existing projects and new product launches.
- Non-GPL: Revenues for 9MFY26 reached ₹13,646 Mn, showing a growth of 16.1% YoY.
- Generic API: Revenues increased by 11.1% QoQ and 1.7% YoY in Q3FY26.
Balance Sheet and Cash Flow
Alivus Life Sciences maintained a strong financial position:
- The company generated a free cash flow of ₹2,207 Mn during 9MFY26.
- Cash and cash equivalents (including short-term investments) totaled ₹7,330 Mn as of December 31, 2025.
Strategic Initiatives and Future Outlook
Alivus Life Sciences is focused on building a sustainable, long-term business through several key strategies:
- Gx API Business: Launching new products, expanding geographically, and focusing on new and regulated markets.
- Capacity Expansion: Continuing greenfield projects in Solapur with 1000MT capacity (with 465KL ongoing), along with expansions in Dahej and Ankleshwar.
- Operational Efficiencies: Debottlenecking processes, backward integration, and adopting flow chemistry in manufacturing.
Source: BSE
